Could the CSL (ASX:CSL) share price get back on track in 2021?

The CSL Limited (ASX: CSL) share price has gone nowhere since March 2020. Citi thinks it could get back on track with the vaccine rollout.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has underperformed the market since the initial COVID-19 sell-off in March 2020. After such a prolonged period of underperformance, Citi thinks the CSL share price could get back on track. 

Strong earnings but plasma collections weigh on CSL share price 

CSL announced a strong half-year report for the six months ended 31 December with group revenue up 16.9% on the prior corresponding period to US$5,739 million. A strong uplift in margins drove its 45% surge in net profit after tax to US$1,810 million. 

At face value, the company's results appear very strong and above CSL's historic mid-teens growth. However, the company did acknowledge that the COVID-19 pandemic had tempered CSL Behring's performance whilst boosting the performance of Seqirus. 

Plasma collections are an essential raw material used in the production of many of the company's therapies. Plasma collection centres and manufacturing facilities are classified as an essential service and remained operational during the pandemic. Despite being open, the company noted in its half-year results that "our plasma collections have been adversely affected during the pandemic". The company reported that collections volumes in December 2020 were ~80% of December 2019 volumes. 

The company has taken several initiatives to improve plasma collections. This includes enhanced targeted marketing initiatives to increase collections, roll out of COVID-19 vaccine to increase social mobility and targeting an additional 12 new centres to be opened in 1H21. 

Citi sees upside to the CSL share price

Citi believes that the current decline in plasma collections is likely to stabilise after the US's COVID vaccine rollout. 

The US has also experienced a significant decline in new daily COVID cases. Its new daily cases surged from an average of 50,000 cases per day in October 2020 to a peak of more than 300,000 cases in January 2021. As of 8 March, the US reported 98,000 cases with a 7-day average of 64,700. 

Citi left its CSL share price target unchanged at $310 with the assumption that plasma donations are back to normal by July 2020. CSL noted that as plasma volumes recover, the cost per litre of plasma reduces, leading to better margins. 

Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares returned to positive territory this Tuesday.

Read more »

Multiple percentage signs in the palm of a man's hand.
Share Market News

ASX 200 lifts on the RBA's latest interest rate call

The ASX 200 is up 0.5% on the heels of the RBA’s interest rate announcement.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Macquarie tips 40% upside for this ASX 200 real estate stock

Let's see what the broker is saying about this stock.

Read more »

Woman sits at her desk working at night, while traffic flows on a busy freeway out the window behind her.
Broker Notes

Transurban shares: Buy, hold, sell? Here's Macquarie's recommendation

Macquarie’s analysts just ran their slide rules over Transurban shares. Here’s what they found.

Read more »

A woman sits at her home computer with baby on her lap, and the winning ticket in her hand.
Consumer Staples & Discretionary Shares

Which 'enduring high-quality business' has become a forgotten ASX 200 stock?

Fundie says this ASX 200 consumer discretionary stock has been flying under investors' radar.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Financial Shares

Want a financial stock outside the big 4 banks? Macquarie tips 15% upside for this small cap financial

For those searching on the edges, this name could be worth a second look according to Macquarie.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Kogan, Monash IVF, OFX, and ResMed shares are falling today

Why are these shares taking a tumble today? Let's find out.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why Breville, Clarity, EOS, and TechnologyOne shares are racing higher today

These shares are having a strong session on Tuesday. But why?

Read more »